Financial Performance - Revenue for the first nine months of 2024 was 298,191,168.41 yuan, a slight increase of 0.66% compared to the same period in 2023[6] - Net profit attributable to shareholders decreased by 12.22% to 57,210,600.07 yuan in the first nine months of 2024[6] - The company's basic earnings per share decreased by 11.36% to 0.39 yuan per share in the first nine months of 2024[6] - The company's weighted average return on equity (ROE) based on net profit attributable to shareholders decreased to 7.60% from 9.01% in the same period last year[6] - Operating income for the first nine months of 2024 was 298,191,168.41, up from 296,228,981.20 in the same period of 2023[24] - Operating costs for the first nine months of 2024 were 237,254,277.75, up from 231,768,499.22 in the same period of 2023[24] - Net profit for the first nine months of 2024 was 60,936,890.66, up from 64,460,481.98 in the same period of 2023[24] - Net profit attributable to parent company owners was RMB 57,210,600.07, compared to RMB 65,178,007.69 in the previous period[25] - Basic earnings per share (EPS) were RMB 0.39, down from RMB 0.44 in the previous period[26] - Operating income for the parent company was RMB 281,028,602.86, up from RMB 274,868,150.85 in the previous period[26] - Total comprehensive income was RMB 68,143,248.42, slightly higher than RMB 67,759,704.66 in the previous period[27] - Fair value change gains were RMB 824,497.91, down from RMB 857,335.25 in the previous period[25] - Credit impairment losses increased to RMB 374,852.36, up from RMB 337,937.21 in the previous period[25] - Operating profit was RMB 66,094,526.60, down from RMB 74,842,617.88 in the previous period[25] - Income tax expenses decreased to RMB 8,983,694.89, down from RMB 9,983,431.82 in the previous period[25] - Minority interest losses were RMB -1,078,177.57, compared to RMB -182,502.47 in the previous period[25] Assets and Liabilities - Total assets increased by 1.96% to 895,388,678.24 yuan as of September 30, 2024, compared to 878,201,606.13 yuan at the end of 2023[5] - The company's debt-to-asset ratio (consolidated) slightly decreased to 14.25% from 14.53% at the end of 2023[5] - Total assets increased to 895,388,678.24 yuan as of September 30, 2024, compared to 878,201,606.13 yuan at the end of 2023[17][19] - Current assets decreased to 488,305,122.02 yuan from 569,701,085.37 yuan, a decline of 14.3%[17] - Non-current assets increased to 407,083,556.22 yuan, up 32.0% from 308,500,520.76 yuan[17][18] - Long-term equity investments grew to 99,001,510.42 yuan, a 59.2% increase from 62,185,570.93 yuan[17] - Intangible assets rose to 95,793,552.83 yuan, up 9.5% from 87,517,526.63 yuan[18] - Development expenditure increased to 39,457,229.53 yuan, a 33.7% growth from 29,504,597.36 yuan[18] - Total liabilities decreased slightly to 127,581,679.03 yuan from 127,599,584.54 yuan[19] - Shareholders' equity increased to 767,806,999.21 yuan, up 2.3% from 750,602,021.59 yuan[19] - Total assets increased slightly from 904,445,831.96 to 907,071,511.67[22] - Fixed assets decreased from 79,777,391.33 to 77,327,877.24[22] - Intangible assets increased from 77,142,378.45 to 82,529,961.25[22] - Development expenditure rose from 26,771,737.91 to 34,891,233.33[22] - Total liabilities decreased from 114,215,377.52 to 99,779,461.81[22] - Total equity increased from 790,230,454.44 to 807,292,049.86[23] Cash Flow - Cash flow from operating activities decreased by 10.96% to 65,490,323.63 yuan in the first nine months of 2024[6] - Net cash flow from investing activities decreased by 79.57% to -21,678,220.42 yuan due to the payment of New Mayo investment[10] - Operating cash flow from sales of goods and services increased to 342.57 million yuan in 2024 from 331.58 million yuan in 2023, reflecting a growth of 3.3%[28] - Total operating cash inflow for 2024 was 346.58 million yuan, compared to 339.61 million yuan in 2023, showing a 2.1% increase[28] - Operating cash outflow for 2024 was 281.09 million yuan, up from 266.05 million yuan in 2023, indicating a 5.6% rise[28] - Net cash flow from operating activities decreased to 65.49 million yuan in 2024 from 73.56 million yuan in 2023, a decline of 11%[28] - Investment cash inflow for 2024 was 1.20 billion yuan, down from 1.28 billion yuan in 2023, a decrease of 6.3%[29] - Net cash flow from investment activities was -21.68 million yuan in 2024, compared to -12.07 million yuan in 2023, showing a 79.6% increase in negative cash flow[29] - Net cash flow from financing activities was -73.41 million yuan in 2024, compared to -56.13 million yuan in 2023, indicating a 30.8% increase in negative cash flow[29] - Total cash and cash equivalents at the end of 2024 were 37.39 million yuan, down from 59.87 million yuan in 2023, a 37.6% decrease[29] - Parent company's operating cash inflow for 2024 was 333.01 million yuan, compared to 325.77 million yuan in 2023, showing a 2.2% increase[30] - Parent company's net cash flow from operating activities decreased to 66.22 million yuan in 2024 from 72.97 million yuan in 2023, a decline of 9.3%[31] Research and Development - R&D expenses increased by 33.02% to 7,785,840.59 yuan due to the initiation of new drug development projects[10] - R&D expenses increased from 5,853,104.09 to 7,785,840.59[24] - R&D expenses increased to RMB 6,149,760.41, up from RMB 4,139,904.21 in the previous period[26] Investments - Investment in New Mayo resulted in a 59.20% increase in long-term equity investments to 99,001,510.42 yuan[9] - Long-term equity investments grew to 99,001,510.42 yuan, a 59.2% increase from 62,185,570.93 yuan[17] Shareholder Information - The total number of shares at the end of the period was 146,546,080, with a decrease of 15,000 shares compared to the beginning of the period[12] - The top 10 shareholders collectively hold 42.1433% of the total shares, with Tang Xian holding the largest share at 22.9455%[13] - The company completed the reserved grant of restricted stock under the 2023 equity incentive plan on September 24, 2024[16] - The company repurchased and canceled 15,000 restricted shares at 2.86 yuan per share for an employee who voluntarily resigned[16] Legal and Compliance - A subsidiary received a fine of 997,800 yuan for producing and selling non-compliant multi-enzyme tablets[16] Inventory and Cash - Cash and cash equivalents decreased to 45,275,416.96 yuan, down 35.8% from 70,478,264.50 yuan[17] - Inventory increased to 46,650,694.15 yuan, a 21.3% rise from 38,471,388.70 yuan[17]
梓橦宫(832566) - 2024 Q3 - 季度财报